Better Access. Better Lives.
We are led by science, driven by passion, and committed to biosimilars. We are continually evaluating additional pipeline opportunities to bring a strategic and robust selection of treatment options to patients around the world.
AVT02
- Biosimilar candidate
- High-concentration, low-volume adalimumab
- Reference biologic
- HUMIRA®
- Therapeutic area
- Immunology
Approved by
- U.S.
- Europe (EEA, UK, Switzerland, Balkans)
- Canada
- Australia
- Saudi Arabia
- Israel
- Egypt
- South Africa
- Morocco
- Peru
- Bolivia
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT04
- Biosimilar candidate
- ustekinumab
- Reference biologic
- STELARA®
- Therapeutic area
- Immunology
Approved by
- U.S.
- Japan
- Canada
- EU/EEA
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT03
- Biosimilar candidate
- denosumab
- Reference biologic
- PROLIA®/XGEVA®
- Therapeutic area
- Bone Disease
Approved by
- Japan
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT05
- Biosimilar candidate
- golimumab
- Reference biologic
- SIMPONI®/SIMPONI ARIA®
- Therapeutic area
- Immunology
Approved by
- Japan
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT06
- Biosimilar candidate
- aflibercept
- Reference biologic
- EYLEA®
- Therapeutic area
- Ophthalmology
Approved by
- EEA
- Japan
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT23*
- Biosimilar candidate
- omalizumab
- Reference biologic
- XOLAIR®
- Therapeutic area
- Respiratory
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT16
- Biosimilar candidate
- vedolizumab
- Reference biologic
- ENTYVIO®
- Therapeutic area
- Immunology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT33
- Biosimilar candidate
- pembrolizumab
- Reference biologic
- KEYTRUDA®
- Therapeutic area
- Oncology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT10
- Biosimilar candidate
- certolizumab pegol
- Reference biologic
- CIMZIA®
- Therapeutic area
- Immunology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT28
- Biosimilar candidate
- ixekizumab
- Reference biologic
- TALTZ®
- Therapeutic area
- Immunology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT48
- Biosimilar candidate
- canakinumab
- Reference biologic
- ILARIS®
- Therapeutic area
- Immunology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT41
- Biosimilar candidate
- guselkumab
- Reference biologic
- TREMFYA®
- Therapeutic area
- Immunology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT65
- Biosimilar candidate
- ofatumumab
- Reference biologic
- KESIMPTA®
- Therapeutic area
- Immunology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT19
- Biosimilar candidate
- dupilumab
- Reference biologic
- DUPIXENT®
- Therapeutic area
- Immunology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
HUMIRA is a registered trademark of AbbVie Inc.
STELARA, SIMPONI and SIMPONI ARIA are registered trademarks of Johnson & Johnson Inc.
XOLAIR, ILARIS and KESIMPTA is a registered trademark of Novartis AG.
PROLIA and XGEVA are registered trademarks of Amgen Inc.
EYLEA and EYLEA HD are registered trademarks of Regeneron Pharmaceuticals Inc. and Bayer AG.
ENTYVIO is a registered trademark of Millenium Pharmaceuticals Inc.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp.
CIMZIA is a registered trademark of UCB Pharma S.A.
DUPIXENT is a registered trademark of Sanofi Biotechnology.
TALTZ is a registered trademark of Eli Lilly and Company.
